Roivant Sciences Ltd.
ROIV
$20.81
-$0.06-0.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -64.89% | -72.84% | -16.08% | -42.05% | 22.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -64.89% | -72.84% | -16.08% | -42.05% | 22.67% |
| Cost of Revenue | 16.10% | 28.30% | 36.90% | 39.81% | 22.95% |
| Gross Profit | -18.75% | -35.58% | -41.83% | -54.86% | -22.96% |
| SG&A Expenses | -34.01% | 37.88% | 128.37% | 31.07% | 121.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.03% | 32.50% | 81.24% | 35.43% | 65.87% |
| Operating Income | 12.33% | -36.63% | -85.71% | -41.92% | -66.66% |
| Income Before Tax | 29.12% | -1,270.99% | -101.58% | -104.55% | 7.05% |
| Income Tax Expenses | -43.85% | -61.14% | 954.34% | -214.32% | 284.98% |
| Earnings from Continuing Operations | 29.89% | -766.72% | -165.78% | -104.07% | 3.19% |
| Earnings from Discontinued Operations | -- | -- | 100.00% | 658.87% | 50.18% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.59% | 33.72% | 46.27% | 118.15% | 85.66% |
| Net Income | 50.68% | -334.38% | -36.63% | -96.68% | 24.36% |
| EBIT | 12.33% | -36.63% | -85.71% | -41.92% | -66.66% |
| EBITDA | 12.10% | -37.47% | -95.25% | -42.81% | -70.46% |
| EPS Basic | 46.74% | -353.51% | -55.10% | -96.32% | 20.78% |
| Normalized Basic EPS | -10.83% | -131.73% | -257.53% | -19.54% | -23.84% |
| EPS Diluted | 45.69% | -354.83% | -56.00% | -96.14% | 20.78% |
| Normalized Diluted EPS | -10.83% | -146.22% | -257.53% | -26.06% | -23.84% |
| Average Basic Shares Outstanding | -7.41% | -7.55% | -11.90% | -9.73% | -4.51% |
| Average Diluted Shares Outstanding | -7.41% | -12.97% | -11.90% | -14.42% | -4.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |